Publications by authors named "H Hjorth-Hansen"
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK cell function with oncological drugs could improve NK cell-based immunotherapies. Here, we used a high-throughput drug screen consisting of over 500 small-molecule compounds to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells.
View Article and Find Full Text PDFThe advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI-insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment and are imperative for disease progression as well as recurrence during treatment-free remission (TFR). Here, we have generated high-resolution single-cell multiomics maps from CML patients at diagnosis, retrospectively stratified by BCR::ABL1 (%) following 12 months of TKI therapy.
View Article and Find Full Text PDFArticle Synopsis
- * At the end of the study, nearly half of the patients were still on treatment, with significant percentages achieving major molecular response (71.8%) and molecular response (59.7%), indicating the drug’s ability to improve disease control.
- * The 48-month survival rate was high (88.3%), and while some adverse events were noted, they were in line with known side effects of bosutinib, highlighting its long-term efficacy and
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively.
View Article and Find Full Text PDFArticle Synopsis
- - The EURO-SKI study, the largest clinical trial on stopping tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia, involved 728 patients and found that 61% maintained major molecular response (MMR) at 6 months and 46% at 36 months.
- - Key factors influencing MMR maintenance included the length of TKI treatment and the patient's deep molecular remission duration before stopping treatment, along with the type of leukemia transcript.
- - For patients experiencing late MMR losses, factors like TKI treatment duration, the presence of blasts in blood, and platelet counts at diagnosis were significant predictors of outcomes during the 36-month follow-up.